USA. SAMHSA provides COVID-19 guidance for opioid treatment programs. 

(…) Disaster plans shall not include any blanket exceptions for clinic closure and/or take- home medication for all patients to include patients who do not qualify for take- home/unsupervised use of opioid pharmacotherapies. Appropriate alternatives compliant with state and federal guidelines for dosing should be arranged for patients who are not eligible for take-home medication. 

SAMHSA will consider approving COVID -19 exceptions to permit dispensing of take- home opioid pharmacotherapy for up to 14 days for those with exposure to COVID-19 or symptomatic for infection when documented by the patient’s healthcare provider. SAMHSA DPT will only consider exception renewals for up to 14 days that are medically indicated and requested by the individual’s healthcare provider. Every exception request for up to 14 days of opioid pharmacotherapy and related to COVID-19 exposure or infection must be presented to the SOTA who will be required to verify that the exception is necessary. (The Substance Abuse and Mental Health Services Administration (SAMHSA), Division of Pharmacologic Therapies (DPT), Center for Substance Abuse Treatment (CSAT), USA, 13.03.2020)

https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines/covid-19-guidance-otp